New and existing investors have laid down $6.9m Series B funding for blood cancer-fighting company OncoPep.
The Leukemia & Lymphoma Society decided to participate in the funding round following its review of OncoPep’s application for funding from the society’s Therapy Acceleration Program which identifies treatments which have the potential to change the standard of care for patients with blood cancers.
Other investors included angel groups, family foundations and individuals.
OncoPep said it will use the funding to support the clinical development of its lead cancer vaccine, PVX-410, which is designed to target tumour antigens associated with plasma cell cancer multiple myeloma.
LLS chief scientific officer Lee Greenberger said, “LLS remains committed to the advancement of promising new treatment options for patients with blood cancers, including those with asymptomatic SMM.
“Every dollar we invest in the development of potential novel treatments brings us closer to our goal of curing leukemia, lymphoma, multiple myeloma and other blood cancers.”
In January this year AVG Ventures and Remeditex Ventures increased their backing of Bellicum Pharmaceuticals to help the company expand the clinical development of its leading cellular immunotherapy product candidates targeting leukaemia and prostate cancer.
Bellicum raised $34.4m Series B funding.
Copyright © 2014 AltAssets